Nicola Mordini
Cuneo, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.
Journal: Bone marrow transplantation
Published: March 02, 2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.
Journal: Bone marrow transplantation
Published: January 21, 2026
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.
Journal: American journal of hematology
Published: August 22, 2025
Unrelated donor transplantation for relapsed refractory aplastic anemia, with quadruple GvHD prophylaxis.
Journal: Bone marrow transplantation
Published: April 13, 2025
Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the "Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare" (GITMO).
Journal: American journal of hematology
Published: January 16, 2025
Perception of 'patient safety culture' among healthcare professionals in the field of haematopoietic stem cell transplantation and CAR-T therapy: a multicentre cross-sectional observational study by Italian Transplant Group for Bone Marrow Transplantation, Haematopoietic Stem Cells and Cell Therapy (GITMO).
Journal: BMJ open quality
Published: January 10, 2025
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation.
Journal: Transplantation and cellular therapy
Published: June 18, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
Journal: Blood cancer journal
Published: June 17, 2024
Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT.
Journal: Blood transfusion = Trasfusione del sangue
Published: March 28, 2024
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT.
Journal: American journal of hematology
Published: August 06, 2023
Last Updated: 09/26/2026